Neurological Emergencies Treatment Trials (NETT) is a clinical trials research company engaged in conducting large simple trials for decreasing burden of illnesses and very acute injuries mainly affecting peripheral nervous system, brain and spinal cord. NETT is a large network dedicated for emergency issues. It is made up of 17 Hub institutions across the nation each with atleast three spoke hospitals. The company research pipeline includes lumbosacral radiculopathy, acute rapid cooling for traumatic injuries of the cord (ARCTIC), platelet-oriented inhibition in new transient ischemic attacks (TIA) trial (POINT), stroke hyperglycemia insulin network effort (SHINE), progesterone for traumatic brain injury experimental clinical treatment (ProTECT), rapid anticonvulsant medication prior to arrival trial (RAMPART) and high-dose albumin therapy for neuroprotection in acute ischemic stroke (ALIAS). The company is headquartered at Ann Arbor in Michigan, the US.